Stocks · News reference
Recursion Pharmaceuticals shares are trading higher after the company announced that Sanofi has optioned the first development candidate from the two companies’ multi-program research collaboration.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Recursion Pharmaceuticals shares are trading after Needham reiterated its Buy rating on the stock and maintained a $8 price target.
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target
Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
Recursion Pharmaceuticals shares rise 0.24% after hours following a $200 million stock offering and a $10 million Sanofi milestone payment.